Magnetic Particle Imaging (MPI) is a tracer-based imaging modality with high spatial and temporal resolution, very promising for cardiovascular imaging and peri-interventional guidance. However, most interventional instruments are invisible in MPI due to a lack of signal generation. Existing instrument marking approaches do not address water durability, which is essential for maintaining temporal consistency during experiments. This study aims to develop a simple and water-stable marking technique with smooth surfaces for interventional devices for preclinical MPI and MRI research. Commercial superparamagnetic iron-oxide nanoparticles (SPIONs) were mixed with a transparent varnish and applied to nitinol stents via dip-coating. An impregnation solution was used to seal the markers. The coating was optically evaluated by microscopy. The water-stability of the markers was assessed after 24 hours in water by Magnetic Particle Spectroscopy (MPS) of the surrounding fluid. The imaging performance of the markers was tested in preclinical MPI and MRI systems. Microscopy showed homogeneous SPION distribution and smooth marker surfaces after the sealing. MPS revealed no detectable signal of the water which surrounded the sealed markers, indicating their water-stability. The MPI-scans demonstrated sufficient visualization of individual markers at the stent ends (SNR=11.5). In MRI, susceptibility artefacts of the marked stents were 4.6 times larger compared to unmarked references. The presented technique allows for easy fabrication of instrument markers with commercially available components for preclinical experiments with the magnetic imaging modalities MPI and MRI.
Magnetic Particle Imaging (MPI) detects superparamagnetic nanoparticles, enabling bimodal contrast with MRI. Resovist®/Ferucarbotran, still used in research, has clinical safety compatibility but suboptimal MPI performance due to many small 5 nm SPIO cores. Magnetic fractionation can enrich larger cores, improving MPI signal and supporting cellular imaging applications. To enable bimodal MRI/MPI and assess in vivo extracellular vesicle (EV) labelling, we characterized the imaging sensitivity and cell-labelling performance of VivoTrax, a commercial formulation similar to Resovist®, and VivoTrax Plus, obtained by magnetic fractionation. VivoTrax Plus showed higher MRI transverse relaxivity and MPI sensitivity than VivoTrax, and both formulations displayed low toxicity toward adipose-derived stem cells (ASCs). VivoTrax Plus allowed MRI detection of small cell numbers, around 100 cells, in agarose phantoms with greater sensitivity than VivoTrax. However, EVs of 30–150 nm isolated from ASCs labelled with VivoTrax Plus did not retain SPIONs, whereas EVs from VivoTrax-labelled ASCs did. Preliminary in vivo experiments in SOD-G93A mice showed MRI-detectable signal voids in the brain after intranasal EV administration, suggesting EV migration to lesioned areas. Overall, magnetic fractionation improves SPION imaging sensitivity but may alter relevant biological properties.
1 February 2026 in International Journal of Nanomedicine
Introduction: Magnetic Particle Imaging (MPI) is a radiation-free imaging modality based on the nonlinear magnetic response of iron oxide nanoparticles, providing high sensitivity and real-time, quantitative, background-free imaging. With the clinical approval of Resotran as an MPI-suitable tracer and the development of first human-scale scanners, clinical applications are within reach. Magnetic Particle Spectroscopy (MPS), the non-imaging counterpart of MPI, enables sensitive analytics by exploiting the signal response of magnetic nanoparticles. In this pilot study, we prove the potential of MPS to continuously monitor blood coagulation in real time. Methods: Blood samples from five volunteers were mixed with the commercial magnetic resonance imaging contrast agent Resotran. The dynamics of the particle signal were assessed in a custom-built MPS-system for a duration of 45 minutes under various conditions, including the presence of anticoagulants (EDTA, Heparin, Citrate) and mechanical stress. The signal amplitude of the fifth harmonic of the MPS was analyzed. To exclude potential thermal effects, the temperature inside the MPS was monitored by using a fiber optic thermometer during the measurements. Results: All Resotran-containing blood samples showed a signal decrease over time. Samples with anticoagulants exhibited no relevant signal decrease (EDTA, Citrate) or a smaller decrease (Heparin) compared to samples without anticoagulants. Additionally, mechanical stress induced a signal decay in all samples, further indicating the link between the observed MPS signal decay and blood coagulation. Conclusion: This study shows that continuous monitoring of human blood coagulation via MPS is feasible, making bedside coagulation monitoring in clinical settings a concrete perspective.
Magnetic Particle Imaging offers unique features for molecular imaging. Its broader use in preclinical research is limited by the accessibility of suitable scanners. To aid in this, a scanner with a mechanically rotated permanent-magnet selection field with a gradient of 2.42 Tm $$^{-1}$$ is presented. It is paired with a modular transmit/receive chain, while feedthrough suppression is provided by a tunable second-order gradiometric receive coil and differential filtering, enabling operation in unshielded environments. The field-generation subsystem requires 413 W, considerably reducing infrastructure demands and permitting long measurements. Within a 40 mm diameter bore, system-matrix reconstruction yields sub-millimeter resolution of $$\le {0.36}$$ mm within a phantom filled with undiluted Perimag plain and a detection limit $$\le$$ 64.4 ng iron in 2D imaging at 1s $$^{-1}$$ rotation. The open software stack and modular hardware facilitate adaptation and scaling. Currently providing 2D images, the platform is poised for 3D through axial translation and algorithmic extensions, offering an accessible, cost-effective route to high-sensitivity preclinical molecular imaging.